In This Article:
For the second day in a row, CVS Health's (NYSE: CVS) stock price saw a satisfying jump on Thursday. It closed the day almost 5% higher, on the back of both lingering optimism and news of another in a series of analyst price target raises. That improvement was markedly better than the performance of the S&P 500 (SNPINDEX: ^GSPC) on the day; it gained slightly over 1%.
One upgrade and a wave of price target increases
The positive investor sentiment on CVS is due to the pharmacy chain operator's fourth-quarter earnings report, which were published early Wednesday morning. The company squeaked past the consensus analyst estimate for revenue, and crushed that for non-GAAP (generally accepted accounting principles) adjusted net income.
Following that, a clutch of analysts wasted little time in raising their price targets on CVS stock -- in one case, even upgrading their recommendation.
This was Leerink Partners' Michael Cherny, who now feels the shares are worthy of an outperform (read: buy) rating; previously he had recommended the company only as market perform (hold). According to reports, he felt that the company's important units -- particularly its Aetna insurance business -- are improving notably, and the stock is now undervalued.
It's buy time, according to some pundits
Cherny's peers weren't as willing to modify their recommendations, yet a handful of them raised their price targets. One of the more aggressive bumps was made by David MacDonald of Truist Securities, who now believes CVS is worth $76 per share, well up from his preceding level of $60. MacDonald reiterated his buy recommendation.
Should you invest $1,000 in CVS Health right now?
Before you buy stock in CVS Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CVS Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $803,695!*
Now, it’s worth noting Stock Advisor’s total average return is 932% — a market-crushing outperformance compared to 176% for the S&P 500. Don’t miss out on the latest top 10 list.
*Stock Advisor returns as of February 7, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Truist Financial. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.
Why CVS Stock Thrashed the Market on Thursday was originally published by The Motley Fool